Intravitreous CytokinE Level in pAtient With retiNal Detachment (ICELAND)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03318588 |
Recruitment Status :
Completed
First Posted : October 24, 2017
Last Update Posted : July 20, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Photoreceptor apoptosis is the basis for permanent visual loss in a number of retinal disorders including age-related macular degeneration (AMD) and retinal detachment (RD). Thus, despite tremendous advances in vitreoretinal surgery and management of rhegmatogenous RD leading to a primary reattachment rate over 95%, some patients show poor visual recovery because of photoreceptor apoptosis.
Physiologically, microglial cells (resident macrophages) are present only in the inner retina. The subretinal space, located between the retinal pigment epithelium (RPE) and the photoreceptor outer segments (POS), is devoid of all mononuclear phagocytes and form a zone of immune privilege. In AMD, several studies showed a strong association between subretinal mononuclear phagocytes infiltration and advanced forms of AMD. Experimental work in mice suggest that this infiltration plays an important role in the pathogenesis of this condition by producing inflammatory cytokines.
RD-induced photoreceptor apoptosis might result from similar mechanisms. The aim of this study is to determine the cytokine profile in vitreous samples from patients with RD and to compare it with those from control patients with macular hole.
Condition or disease | Intervention/treatment |
---|---|
Retinal Detachment | Procedure: Vitrectomy |
Study Type : | Observational |
Actual Enrollment : | 74 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Intravitreous CytokinE Level in pAtient With retiNal Detachment |
Actual Study Start Date : | November 15, 2017 |
Actual Primary Completion Date : | June 28, 2018 |
Actual Study Completion Date : | October 11, 2018 |

Group/Cohort | Intervention/treatment |
---|---|
Case
Patients undergoing vitrectomy for primary retinal detachment
|
Procedure: Vitrectomy
Pars plana vitrectomy |
Control
Patients undergoing vitrectomy for idiopathic macular hole
|
Procedure: Vitrectomy
Pars plana vitrectomy |
- Intravitreous cytokine levels [ Time Frame: up to one month after surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with primary retinal detachment requiring vitrectomy
- Patients with idiopathic macular hole requiring vitrectomy
Exclusion Criteria:
- History of retinal detachment or intraocular inflammatory diseases

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03318588
France | |
Brabois Hospital | |
Vandœuvre-lès-Nancy, France, 54500 |
Principal Investigator: | Jean-Baptiste CONART, MD | Brabois Hospital, Department of Ophthalmology |
Responsible Party: | Docteur Jean-Baptiste CONART, Medical Doctor, Central Hospital, Nancy, France |
ClinicalTrials.gov Identifier: | NCT03318588 |
Other Study ID Numbers: |
2017-A02195-48 |
First Posted: | October 24, 2017 Key Record Dates |
Last Update Posted: | July 20, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Retinal detachment Photoreceptor apoptosis Cytokine |
Retinal Detachment Dissociative Disorders Mental Disorders Retinal Diseases Eye Diseases |